Featured Articles

Concert Pharmaceuticals asserted the next development candidate CTP-692, a novel drug for adjunctive treatment of schizophrenia, a devastating, chronic illness with significant unmet…
Read More...

Apnea Sciences Corporation asserted the availability of SnoreRx at selected CVS pharmacies. FDA has sanctioned SnoreRx to be denoted as the first and only oral appliance for treatment…
Read More...

Second Genome which is considered a leader in the development of novel medicines derived from the human microbiome initiated four collaborations with key academic institutions to assess…
Read More...

Spruce Biosciences which is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders asserted the launch of its Congenital Adrenal Hyperplasia…
Read More...

OrthoSpin which is a portfolio company of the Trendlines Group declared that it had successfully completed a first-in-human case for smart, robotic external fixation system assuring…
Read More...

Celltex Therapeutics Corporation asserted its authorization to conduct an investigational protocol which is a Phase II B Wellness Protocol Clinical Study on Rheumatoid Arthritis and…
Read More...

Aridis Pharmaceuticals applying proprietary technologies to curate novel anti-infectives and immunotherapies for infectious diseases proclaimed that it has created a Joint Venture with …
Read More...

Beacon Discovery asserted the formulation of a multi-year drug discovery collaboration with Takeda Pharmaceutical Company aiming to develop G-protein coupled receptors paving way for…
Read More...

Longeveron asserted that its revolutionary Clinical Trial initiated to treat infants with Hypoplastic Left Heart Syndrome as the first patient received the treatment using the company's…
Read More...

Medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, Access Vascular asserted that the Company has sought …
Read More...

PharmaCyte Biotech aiming to develop targeted cellular therapies for Cancer and diabetes using its signature  live-cell encapsulation technology, Cell-in-a-Box, announced that its…
Read More...

Pharmaceutical company, Neumentum committed to transforming the way acute and chronic pain are treated-without  opioids asserted the confirmation of Type B meeting with the U.S FDA…
Read More...

EpimAb Biotherapeutics which is essentially a biologics company based in Shanghai, China emphasizing on developing a portfolio of bispecific antibodies declared the appointment of Bin…
Read More...

Genomic Health asserted the U.S commercial launch of  Oncotype DX AR-V7 Nucleus Detect test. The Oncotype DX AR-V7 Nucleus Detect test was developed by Epic Sciences to help prolong the…
Read More...

CE Mark approval was sought for EPD's Cardiac Mapping and Navigation System. The system helps electrophysiologists navigate the heart by generating a succinct 3D Map while imaging and…
Read More...

Atrium Health's Levine Children's Hospital proved to be a new trial site to test a new medicine for children that can regulate and stabilize their blood pressure in fatal circumstances.…
Read More...

Leading innovator in  treatments for atrial fibrillation (Afib), AtriCure and left atrial appendage management (LAAM) announced the rolling out of AtriClip FLEX•V Left Atrial Appendage…
Read More...

Alfa Scientific Designs, the US manufacturer of rapid, point-of care medical devices asserted that the FDA has extended the 510(k) clearance for  ALFA's iFOB with Driven Flow…
Read More...

Surgical guidance company, Endomag asserted that it has sought 510 (k) clearance from the US Food and Drug Administration to further extend the indication of its Magseed magnetic marker…
Read More...

Pfizer asserted that the Committee for Medicinal Products for human use of the European Medicines Agency has disapproved of expanding use of SUTENT to encompass the adjuvant treatment…
Read More...